Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on June 11.

Matt Phipps has given his Buy rating due to a combination of factors that highlight the potential of Upstream Bio, Inc.’s drug, verekitug. The company presented compelling pharmacology modeling data at the EAACI Congress, which demonstrated a differentiated efficacy profile for verekitug by targeting the TSLP receptor rather than the TSLP ligand. This approach is believed to allow verekitug to achieve higher potency at lower doses compared to its competitor, Tezspire.
Furthermore, verekitug is currently the only anti-TSLPR antibody in clinical development, which positions it uniquely in the competitive landscape. The pharmacokinetic and pharmacodynamic models showed good alignment with clinical data, indicating strong potential for efficacy. Upcoming Phase II data in chronic rhinosinusitis with nasal polyps, expected in the third quarter, is anticipated to be a significant catalyst for the company’s stock performance.

According to TipRanks, Phipps is an analyst with an average return of -8.7% and a 39.37% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Incyte, Genmab, and Cullinan Management.